Abstract
| Original language | English |
|---|---|
| Article number | CD014510 |
| Journal | Cochrane Database of Systematic Reviews |
| Volume | 2023 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 30 Jan 2023 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cochrane Database of Systematic Reviews, Vol. 2023, No. 1, CD014510, 30.01.2023.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies
AU - Raaphorst, Joost
AU - Gullick, Nicola J.
AU - Pipitone, Nicolo
AU - Shokraneh, Farhad
AU - Brassington, Ruth
AU - Ali, Saadia Sasha
AU - Gordon, Patrick A.
N1 - Funding Information: My position as Managing Editor at Cochrane Neuromuscular is supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health. Cochrane Neuromuscular is also supported by the Queen Square Centre for Neuromuscular Diseases. Funding Information: The methods section of the review have been developed using text from a standard protocol adapted by Cochrane Neuromuscular from a template developed by Cochrane Airways. This is a new protocol for an update of Gordon 2012, with a revised scope. This project was supported by the National Institute for Health Research (NIHR) via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health. Cochrane Neuromuscular is also supported by the MRC Centre for Neuromuscular Diseases. Our thanks to Andrea Takeda for copy editing the manuscript and to peer reviewers: Nuala Livingstone, Cochrane Evidence Production and Methods Directorate, Stephanie Keeling MD MSc FRCP(C), Professor of Medicine, Division of Rheumatology, University of Alberta; and Catrin Tudur Smith, University of Liverpool. Funding Information: This project was supported by the National Institute for Health Research (NIHR) via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health. Cochrane Neuromuscular is also supported by the MRC Centre for Neuromuscular Diseases. Funding Information: NG: declares clinical trial contracts to her institution from Izana Bioscience, Astra Zeneca, Eli Lilly, and Novartis. She has received honoraria for lectures and educational events from Abbvie, Celgene, Janssen, Eli Lilly, Novartis, and UCB. She has received support for conference attendance from Celgene, Janssen, Eli Lilly, and UCB and payment for Advisory Boards relating to treatment of psoriatic arthritis and axial spondyloarthropathy from Abbvie, Janssen, Novartis, and UCB. NG is a consultant physician involved in the care of patients with inflammatory myositis at the University Hospital Coventry & Warwickshire. The ARTEMIS study (of abatacept in myositis) was carried out as an investigator-initiated study funded by a grant from Bristol-Myers Squibb (BMS), the Myositis Support Group, and Börje Dahlin Foundation, Swedish Research Council GRANTK2014-52X-14045-14-3, Swedish Rheumatism Association, King Gustaf V 80-Year Foundation, and the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet. BMS provided the study drug. The presented work was initiated, conducted and performed independently of BMS. Funding Information: PG: PG's institution has received funding for five studies relevant to this review. One was a study (Chung 2007), funded by various noncommercial grant-giving bodies, one study (ARTEMIS, NCT01315938) was funded in the UK by Bristol Myers Squibb and the Myositis Support Group and one by the Arthritis Research Campaign (SELAM, ISRCTN40085050). One study was a commercial trial funded by Corbus Pharmaceuticals. Inc (DETERMINE, NCT03813160), and one is ongoing, funded by Eli Lilly (MYOJAK, NCT04208464). PG's institution has received a grant from Corbus Pharmaceuticals. PG had or has control of or access to the institutional grants for the ARTEMIS, DETERMINE and MYOJAK trials and the Corbus Pharmaceuticals grant. He received personal payments for an Eli Lilly International Systemic Lupus Erythematosus Advisory Board in December 2020, a speaker's honorarium from UCB in 2021, and consultancy fees from Galapagos in 2023. He was funded to attend the EULAR e-congress in 2020 by AbbVie and has also been funded by other drug companies to attend meetings in the past. He was due to be an investigator for the study NCT02612857, a commercial trial funded by Idera Pharmaceuticals Inc, and was an author on an abstract presenting the protocol but had to withdraw from the study in 2017 due to personal illness. Publisher Copyright: Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2023/1/30
Y1 - 2023/1/30
N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. This protocol is for two separate reviews to assess the effects (benefits and harms) of immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies. Targeted treatments To assess the effects (benefits and harms) of targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies: dermatomyositis (DM, including juvenile dermatomyositis, jDM), immune mediated necrotising myopathy (IMNM), anti-synthetase syndrome (ASS), overlap-myositis (OM) and polymyositis (PM). We will also include cancer-related myositis and amyopathic dermatomyositis. Non-targeted treatments To assess the effects (benefits and harms) of non-targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies: dermatomyositis (DM, including juvenile dermatomyositis, jDM), immune mediated necrotising myopathy (IMNM), anti-synthetase syndrome (ASS), overlap-myositis (OM) and polymyositis (PM). We will also include cancer-related myositis and amyopathic dermatomyositis.
AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. This protocol is for two separate reviews to assess the effects (benefits and harms) of immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies. Targeted treatments To assess the effects (benefits and harms) of targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies: dermatomyositis (DM, including juvenile dermatomyositis, jDM), immune mediated necrotising myopathy (IMNM), anti-synthetase syndrome (ASS), overlap-myositis (OM) and polymyositis (PM). We will also include cancer-related myositis and amyopathic dermatomyositis. Non-targeted treatments To assess the effects (benefits and harms) of non-targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies: dermatomyositis (DM, including juvenile dermatomyositis, jDM), immune mediated necrotising myopathy (IMNM), anti-synthetase syndrome (ASS), overlap-myositis (OM) and polymyositis (PM). We will also include cancer-related myositis and amyopathic dermatomyositis.
UR - http://www.scopus.com/inward/record.url?scp=85147215297&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/14651858.CD014510
DO - https://doi.org/10.1002/14651858.CD014510
M3 - Review article
SN - 1465-1858
VL - 2023
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 1
M1 - CD014510
ER -